1087-107 Transforming growth factor beta and factor XIIIa are constituents of the carcinoid heart endocardial layer: A study by confocal laser microscopy  by Maisch, Bernhard et al.
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1087-103 Plasma Metalloproteinase Levels Are Correlated With 
Natriuretic Peptide and Endothelin-1 Levels in Patients 
With Heart Failure
Raymond T. Yan, Andrew T. Yan, Himali R. Gunasinghe, Peter P. Liu, Francis G. Spinale, 
Robert S. McKelvie, McMaster University, Hamilton, ON, Canada, University of Toronto, 
Toronto, ON, Canada
Background: Several neurohormones can activate matrix metalloproteinases (MMPs)
which regulate extracellular matrix turnover and left ventricular (LV) geometry in the fail-
ing myocardium. However, the relationships between the various neurohormonal and
MMP systems in heart failure (HF) have not been elucidated.
Methods: Patients with symptomatic HF and LV ejection fraction <0.40 were randomized
in the RESOLVD trial to various combination regimens of candesartan, enalapril, and
metoprolol. In this substudy, plasma MMP-2, MMP-9, tissue inhibitor of metalloprotein-
ase-1 (TIMP-1), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), angio-
tensin-II, aldosterone, and endothelin-1 were measured by ELISA in 184 patients at
baseline. Epinephrine and norepinephrine were measured by HPLC.
Results: The relationships between plasma MMP and neurohormone levels are tabu-
lated below. 
*P<0.001
**P<0.01
†P<0.05
Conclusion: Increased plasma MMP-2 and TIMP-1 levels were related to elevated levels
of ANP, BNP and endothelin-1. In contrast, the renin-angiotensin-aldosterone and the
sympathetic nervous systems, both of which have been historically associated with pro-
moting fibrosis, did not correlate with MMP levels. Therefore, MMP and TIMP levels
appear to be differentially regulated by certain bioactive signals, rather than a non-spe-
cific global induction in HF. These new findings suggest that these proteolytic pathways
can be modified through selective pharmacological targets.
1087-104 Pioglitazone Modulates Collagen Synthesis in 
Fibroblasts in Response to Angiotensin II
Kui Chen, Dayuan Li, Xing Jiang Zhang, Jawahar L. Mehta, University of Arkansas for 
Medical Sciences, Little Rock, AR, Central Arkansas Veterans Healthcare System, Little 
Rock, AR
Background and Objectives: Angiotensin II (Ang II) and free radicals are potent media-
tors of ischemic cardiac dysfunction. Fibroblast growth and activity (collagen formation)
characterize this process in response to Ang II and free radicals. Recent studies suggest
that PPAR-γ ligands have the potential to modulate the process of acute ischemic injury
and its long-term consequences. This study examined the modulation of fibroblast activa-
tion in response to Ang II by the PPAR-γ ligand pioglitazone.
Methods and Results: Cultured rat cardiac fibroblasts were treated with Ang II (10-8 to
10–6 M) for 12 hrs. Parallel sets of fibroblasts were pretreated with pioglitazone (10-6 M)
before exposure to Ang II (10-7 M). Treatment with Ang II resulted in increased collagen-1
and reduced MMP-1 protein expression in cardiac fibroblasts (both P<0.01). Ang II treat-
ment also reduced protein kinase B (PKB)/Akt expression. Pretreatment of cells with
pioglitazone completely blocked the decreased PKB/Akt expression in Ang II–treated
cells, and simultaneously inhibited the effects of Ang II on collagen and MMP expression
(all P<0.01 vs. Ang II alone).
Conclusion: This study shows that Ang II enhances collagen and reduces MMP-1 pro-
tein expression in fibroblasts. Importantly, pioglitazone blocks these effects of Ang II,
most likely by PKB/Akt activity in fibroblasts.
1087-105 Synergistic Effects of the Addition of Candesartan to 
Enalapril on Myocardial Fibrosis and Left Ventricular 
Diastolic Function in Dogs With Heart Failure
Kaoru Funabiki, Katsuya Onishi, Kaoru Dohi, Takafumi Koji, Masaki Tanabe, Tetsuya 
Kitamura, Masaaki Ito, Takeshi Nakano, Mie University School of Medicine, Tsu, Japan
Backgrounds: Angiotensin II (AngII) type 1 receptor blocker, candesartan reduced rele-
vant cardiovascular events when added to ACE inhibitors in patients with congestive
heart failure (CHF). Candesartan prevents myocardial fibrosis due to the effective inhibi-
tion of AngII in animals with non-ACE pathway, while ACE inhibitor acts on myocardial
fibrosis partly through the bradykinin-mediated mechanism as well as the inhibition of
AngII. Therefore, we hypothesized that the addition of candesartan to enalapril synergis-
tically prevented myocardial fibrosis and improved left ventricular (LV) diastolic function to
the greater extent than each drug alone in CHF. Methods: Twenty-eight dogs were
assigned to the following treatment protocols on the 8th day of a 4-week rapid pacing: (A)
rapid ventricular pacing (240 bpm, n=7), (B) enalapril (1.9 mg/kg/day) and pacing (n=7),
(C) candesartan (1.5 mg/kg/day) and pacing (n=7), (D) combined enalapril (0.95 mg/kg/
day) and candesartan (0.75 mg/kg/day) and pacing (n=7).
Results: Although there was no difference in myocardial AngII levels among all groups,
concomitant use of enalapril and candesartan significantly decreased LV end-diastolic
pressure and LV stiffness estimated by LV pressure-volume plane to the greater extent
than each drug alone. Furthermore, it suppressed the expression of the collagen-type 1
and 3 mRNA (p<0.05) and decreased the values of LV collagen volume fraction evalu-
ated with picrosirius red stain (A 6±1, B 4±1*, C 3±1*†, D 2±1*†‡ %, respectively; *p<0.05
vs. A, †p<0.05 vs. B, ‡p<0.05 vs. C). Conclusion: Concomitant use of enalapril and can-
desartan synergistically prevented LV fibrosis and improved LV diastolic function during
the development of CHF. Thus, the addition of candesartan to ACE inhibitor may become
an important strategy for the prevention of cardiac remodeling.
1087-106 Early Serum Levels of Tissue Inhibitor of 
Metalloproteinases-1 but Not Matrix Metalloproteinase-1 
Are Associated With Cardiovascular Death After 
Complicated Myocardial Infarction
Cord A. Manhenke, Stein Ørn, Faiez Zannad, Torbjørn Aarsaland, Kenneth Dickstein, 
The OPTIMAAL Trial Study Group, Rogaland Central Hospital, Stavanger, Norway
Background: The complex process of early remodeling in acute myocardial infarction
(AMI) involves activation of matrix metalloproteinases (MMPs). We related increased
serum levels of MMP-1 and type1-tissue inhibitor of matrix metalloproteinases (TIMP-1)
to adjudicated cardiovascular mortality in patients following complicated AMI.
Methods: Serum from 233 patients in the OPTIMAAL trial which included patients follow-
ing AMI with heart failure and/or left ventricular dysfunction was sampled at randomiza-
tion (mean 3 days after index MI).
Results: Mean MMP-1 and TIMP-1 for all patients were 6.5 (+ 6.6) and 1610 (+ 623) ng/
ml respectively. During a mean follow-up of 2.6 years cardiovascular death occurred in 29
patients. Non-survivors had significantly higher serum levels of TIMP-1 but not MMP-1
compared to survivors during follow-up (mean 1960 (+749) vs. 1660 (+588) ng/l, p=.003
for TIMP-1 and mean 8.2 (+7.9) vs. 6.2 (+6.4) ng/ml, p=.097 for MMP-1). Patients above
and below mean TIMP-1 values had a mortality rate of 18.1% and 9.5% respectively (log
rank p=.031) (fig.).
Conclusion: Increased levels of TIMP-1 are associated with increased cardiovascular
mortality following high risk AMI. As TIMP-1 also is upregulated by free MMPs other than
MMP-1 this finding suggests that other MMP subtypes are activated during the acute
phase following complicated AMI. 
1087-107 Transforming Growth Factor Beta and Factor XIIIa Are 
Constituents of the Carcinoid Heart Endocardial Layer: 
A Study by Confocal Laser Microscopy
Bernhard Maisch, Dorgit Diepholz, Reinhard Funck, Andreas Wilke, Rudi Arnold, 
Philipps-University, Marburg, Germany
The detailed composition of the carcinoid right ventricular endocardial layer and the
pathogenesis are still unresolved. One common explanation is that fibrosis occurs as a
consequence to microlesions induced by high levels of circulating serotonin and bradyki-
nin.
Methods: The right ventricular endomyocardial biopsies of 7 patients (5 female, mean
age 43,9 + 11,4 y) with established carcinoid syndrome and right ventricular disease
Kendall’s tau correlation MMP-2 MMP-9 TIMP-1
ANP 0.26 * 0.060 0.21 *
BNP 0.21 * 0.030 0.14 **
Angiotensin-II -0.084 0.067 -0.079
Aldosterone 0.005 0.096 -0.061
Epinephrine 0.067 0.025 0.005
Norepinephrine 0.041 -0.006 0.047
Endothelin-1 0.11 † 0.010 0.15 **
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were analysed immunohistochemically by confocal laser microscopy for the composition
of the the carcinoid endomyocardial tissue components using specific antibodies against
collagen I and III, factor XIIIa, TGF beta and laminin.
Results: The main component of the carcinoid membrane is collagen I, followed by col-
lagen III. The layer is extremely rich with nuclei. - In the subendocardium the laminin sur-
rounds hypertrophic and pycnic myocytes with lipofucein deposits. The regular structure
of normal endomyocardium is disolved, disarray becomes a prominent feature. The carci-
noid membrane itself does not contain laminin, however. – In the borderzone between the
carcinoid membrane and the myocardium a lining of TGF beta positive cells is found reg-
ularly. From there factor XIII positive cells disperse into the surrounding myocytes.
Conclusion: To the best of our knowledge this is the first description that the 2 proteins
TGF beta and factor XIIIa are regular constituants in the carcinoid fibrous plaque in right
ventricular endomyocardium. Both proteins are known to contribute to inflammation and
healing in general. Their presence in the endomyocardium substantiates the „response
to injury hypothesis“ for the pathogenesis of the carcinoid heart.
1087-108 Enhanced Instability of Membranous Type 1 Matrix 
Metalloproteinase in Response to Mechanical Loading 
in Left Ventricular Myocardium
Toshihiro Tsuruda, Lisa C. Costello-Boerrigter, Ondrej Lisy, Brenda K. Huntley, Margaret 
M. Redfield, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background The extracellular matrix (ECM) is essential for maintaining the structural
integrity of the heart. Among matrix metalloproteinases (MMPs), membranous type 1
MMP (MT1-MMP) is recognized to be a key enzyme by degrading ECM proteins directly
as well as by activating the other MMPs, including MMP-2. However, it remains to be elu-
cidated if mechanical loading and unloading influence the process of MT1-MMP activity.
We therefore investigated whether mechanical load is responsible for MT1-MMP activity
and consequently affects the induction of MMP-2 activity in ventricular myocardium.
Methods and Results Unloading (UL, n=5) and loading (LO, n=5) of the left ventricle in
dogs were achieved by constriction of the inferior vena cava and by rapid ventricular pac-
ing (180 beats/min) for 10 days, respectively. Although the expression of the active form
(57-kDa) of MT1-MMP in UL and LO did not differ from control (n=6), the inactive form of
MT1-MMP (43-kDa) significantly (p<0.01) increased by 158% in LO, and significantly
(p<0.05) decreased by 55% in UL, assessed by Western blotting. In addition, tissue
inhibitor of MMP (TIMP)-2 significantly (p<0.01) decreased by 56% with the reduction of
zymographic MMP-2 activity in LO.
Conclusion In summary, mechanical loading initiates the autocatalysis of active form
MT1-MMP into inactive form concomitant with TIMP-2 reduction, resulting in decreasing
MMP-2 activity. These in vivo findings suggest that ECM degradation pathway mediated
by MT1-MMP down-regulates in response to mechanical loading to counteract against
the overload. Thus, we speculate the important compensatory biological system of
MMPs/TIMPs for maintaining the adequate ECM circumstance in the development of
heart failure.
1087-133 Assessment of Ventricular Untwisting Recoil Velocity by 
Doppler Tissue Echocardiography: An Index of 
Relaxation Time Constant
Yuichi Notomi, Takahiro Shiota, Zoran B. Popovic, Hirotsugu Yamada, Maureen G. 
Martin-Miklovic, Dimitri G. Deserranno, Don W. Wallick, Neil L. Greenberg, Mario J. 
Garcia, James D. Thomas, Cleveland Clinic Foundation, Cleveland, OH
Background- The rate of recoil of left ventricular (LV) torsion that occurs during isovolu-
mic relaxation, when determined by tagged magnetic resonance imaging (MRI), is a
strong predictor of the relaxation time constant (τ). Doppler tissue echocardiography
(DTE) can detect myocardial velocity directly with higher spatio-temporal resolution than
MRI. We assessed the relationship between τ and LV untwisting velocity (LV-UV) mea-
sured by DTE.
Methods and Results- We obtained micromanometer-recorded LV pressures and DTE
data in 4 anesthetized closed-chest dogs at baseline, during right and left ventricular pac-
ing, and during dobutamine and esmolol infusion (total 21 stages). τ was calculated by
the equation: LVP = P0*e^(-t/τ) + Pb. LV-UV (rad/s) was defined as the difference
between rotational velocities at the basal and apical short-axis levels of the LV. The rota-
tional velocity was calculated from the septal and lateral regional velocity obtained from
the LV short-axis and corrected by the instantaneous LV radius. The LV-UV showed a
strong nonlinear relation with τ (r = 0.80, p < 0.001, see figure). LV-UV showed moderate
correlation with minimum dP/dt (r= 0.41, p = 0.05 by repeated-measures linear regres-
sion).
Conclusions- Ventricular untwisting recoil rate, as determined by DTE using our novel
method, may facilitate measurement of LV pressure decay as an index of relaxation. This
method may provide an estimation of ventricular relaxation in individual patients, allow
serial noninvasive evaluations. 
1087-134 Improved Calcium Homeostasis and Antiarrhythmic 
Effects of a Novel Chimeric Molecule That Inhibits Both 
Type III Phosphodiesterase and L-Type Calcium 
Channel in Failing Hearts
Reza Mazhari, Katayoun Derakhchan, Gregory Hamilton, Marc-Antoine Gillis, Daniel 
Bednarik, Peter Suzdak, Stanley Nattel, Artesian Therapeutics, Gaithersburg, MD, 
Montreal Heart Institute, Montreal, PQ, Canada
Background: Congestive heart failure (CHF) is becoming an increasing contributor to
mortality rate as a function of the aging population. Because of their ability to improve
cardiac performance and symptoms of decompensation, phosphodiesterase inhibitors
(PDEI) have been used in the treatment of patients with severe CHF. However, several tri-
als have shown that PDEIs result in a >25% increase in mortality rate, apparently due to
arrhythmias. We have developed a novel dual-pharmacophore compound (ATI22107)
designed to simultaneously inhibit the cardiac phosphodiesterase PDE3 and the L-type
calcium channel (LCC). We hypothesized that ATI22107 would preserve the beneficial
effects of a pure PDEI, while minimizing deleterious responses through antagonism of
LCC.
Methods: Hemodynamic, echocardiograph, and electrocardiogram data were measured
in anesthetized dogs with tachycardia-induced (220-240 bpm x 5 weeks) CHF. Effects of
graded intravenous doses of ATI22107, and a pure PDEI, milrinone (Mil), on hemody-
namic and arrhythmic indices were compared to those of vehicle control.
Results: Both ATI22107 and Mil resulted in a comparable decline in mean arterial pres-
sure and left ventricular end-diastolic pressure, while heart rate increased <5% in both
groups at all doses. However, Mil infusion resulted in non-sustained ventricular tachycar-
dia (frequency of 173±12 bpm, mean±SEM) at all doses, while none were observed with
ATI22107. ATI22107 produced a dose-dependent increase in the rate of ventricular relax-
ation (-dP/dtmin), with a maximal increase of 120±7% of control, 87% of the maximal
effect of Mil (138±11%). ATI22107 also produced a dose-dependent increase in +dP/
dtmax, ejection fraction, and fractional area shortening, with the maximal increase in con-
tractile indices at the highest dose being only 55 - 70% of the maximal effect of Mil.
Conclusions: ATI22107 improves hemodynamic indices in dogs with CHF, and has
selective lusitropic effects. This novel pattern of hemodynamic action, coupled with a
reduced arrhythmogenic profile, may make ATI22107 a promising agent for CHF therapy,
particularly in patients with a significant component of diastolic dysfunction.
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1088-115 Partial Fatty Acid Inhibition by Trimetazidine Improves 
Left Ventricular Function in Patients With Heart Failure 
of Different Etiologies
Gabriele Fragasso, Altin Palloshi, Carmen Silipigni, PierMarco Piatti, Lucilla Monti, 
Emanuela Setola, Giorgio Bassanelli, Chiara Montano, Alberto Margonato, Istituto 
Scientifico/Universita' San Raffaele, Milano, Italy
We assessed whether the addition of the partial fatty acid inhibitor trimetazidine (TMZ) to
standard conventional therapy (CT) in patients (pts) with heart failure, can effectively
improve symptoms, resting left ventricular function and exercise tolerance. Forty-one pts
(37 males, age 64±4 yrs) were randomly allocated in an open label fashion to either CT
(21 pts) or conventional therapy plus TMZ (20 mg tid) (20 pts). All pts underwent 2D-
echocardiography and exercise testing before and at follow up (11±3 months). NYHA
functional class, ejection fraction (EF-%), exercise time (ET-sec) and metabolic units dur-
ing exercise (METS-3.5 ml O2/kg * min) were evaluated. Physicians performing func-
tional tests were blind to patients’ treatment arm. At baseline NYHA class, EF (37±8 vs
38±8), exercise time (411±129 vs 397±143) and METS (7.2±3.1 vs 7.8±2.5) were not dif-
ferent in the TMZ and CT groups, respectively. At follow-up, in the TMZ group 11 pts
improved NYHA class and none worsened, while in CT NYHA class improved only in 2
pts and worsened in other 2. EF significantly increased in TMZ pts compared to CT
(43±9 vs 35±8, p=0.008). Finally, although not significantly, exercise time (414±166 vs
359±137, p=0.25) and METS (8.5±2.7 vs 7.7±1.7, p=0.26) tended to be higher in TMZ
pts. In conclusion, long term TMZ, by shifting the energy substrate preference away from
fatty acid metabolism and toward glucose metabolism, improves left ventricular function
and symptoms in pts with heart failure, regardless of its etiology. The observed TMZ ben-
efit contrasts with the natural history of the disease, as confirmed by the mild but consis-
tent decrease of EF in pts when on CT only. Whether these benefits would translate into
improved survival should be ascertained by a multicenter trial.
